Diffuse large B-cell lymphoma (DLBCL) is a diverse group of B-cell lymphomas that vary in their clinical characteristics. Usually manifesting as a rapidly progressing or advanced condition, it is often curable even at advanced stages. The illness originates in extranodal and extramedullary tissues in 40% of patients. Patients over the age of 80 who have comorbidities or fragile conditions may be eligible for Rituximab and Reduced Dose CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) (R-mini-CHOP) chemoimmunotherapy. We report a 75-year-old woman with a tumor on the right side of the nose that covers the eye, so it is easy to fall out. The diagnosis of DLBCL (sinonasal) was made on the basis of computed tomography (CT) scan of the paranasal sinuses with contrast and immunohistochemical examination. Due to the age of the patient, who was included in the very elderly category with moderate frailty based on instrumental activities of daily living (IADLs), the patient was given R-mini-CHOP chemoimmunotherapy for six cycles, followed by radiation as much as 20 × 18 Gray (Gy) where the patient in the final evaluation stated complete response.
No takes yet. Share an insight, caveat, or question.
Syarifuddin et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: